The Conversation (0)
Chart
Detailed Quote
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease.
Featured Articles and Interviews
Jun 02, 2026
5 Biggest Biotechnology ETFs in 2026
Press Releases
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
